Xeris Biopharma Holdings, Inc. today announced financial results for the fourth quarter and full-year 2022 and provided 2023 financial guidance.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors.
Alnylam Announces Appointment of Peter Kellogg to Board of Directors Read More »
BioMarin announced Tuesday that the FDA has accepted its supplemental New Drug Application to expand Voxzogo for children younger than five years with achondroplasia.
BioMarin Answers BridgeBio’s Challenge with sNDA for Achondroplasia Read More »
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) notified the companies that the agency does not currently plan to convene an advisory committee meeting to discuss the New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression
Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone Read More »
En este Short nos preguntamos si las serpientes, que carecen de oídos visibles, pueden realmente escuchar lo que ocurre en su entorno. …
Sumitomo Heavy Industries, Ltd. announced the decision to invest in Alpha Fusion Inc., a developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy.
JW Therapeutics announced the initiation of clinical study of Carteyva® for first-line treatment in patients with high-risk large B-cell lymphoma and the first patient infusion.
Bio-Thera Solutions, Ltd., a commercial-stage pharmaceutical company, announced that dosing has begun in a Phase 1 clinical study evaluating BAT8008, an antibody-drug conjugate that targets Trop2.
Tessa Therapeutics Ltd. announced entry into a Cooperative Research and Development Agreement with the U.S. National Cancer Institute, part of the National Institutes of Health, to investigate TT11X, Tessa’s allogeneic “off-the-shelf” CD30.CAR-modified Epstein-Barr virus-specific T-cell therapy, in multiple subtypes of non-Hodgkin lymphoma.
The past two decades were all about nucleic acid reading and writing. The next is about delivering DNA and RNA, Yogev Debbi, CEO of Mana.bio, told BioSpace in an interview.
